1. Home
  2. MLTX

as of 12-09-2025 3:46pm EST

$14.59
$0.48
-3.19%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.

Chart Type:
Time Range:
Founded: 2021 Country:
Switzerland
Switzerland
Employees: N/A City: ZUG
Market Cap: 972.7M IPO Year: N/A
Target Price: $36.33 AVG Volume (30 days): 2.0M
Analyst Decision: Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.33 EPS Growth: N/A
52 Week Low/High: $5.95 - $62.75 Next Earning Date: 11-05-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered MLTX Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 66.44%
66.44%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of MoonLake Immunotherapeutics (MLTX)

Bodenstedt Matthias

Chief Financial Officer

Buy
MLTX Oct 8, 2025

Avg Cost/Share

$9.09

Shares

10,870

Total Value

$98,808.30

Owned After

627,536

SEC Form 4

Sell
MLTX Sep 30, 2025

Avg Cost/Share

$6.96

Shares

5,827

Total Value

$40,555.92

Owned After

1,994,173

SEC Form 4

Sell
MLTX Sep 29, 2025

Avg Cost/Share

$7.99

Shares

6,494,151

Total Value

$46,827,628.18

Owned After

1,994,173

SEC Form 4

Share on Social Networks: